



MEDIA ADVISORY

South Africa gets update on large-scale HIV vaccine efficacy trials

HIV Vaccine Trials Network (HVTN) set to engage communities at [9th SA AIDS Conference](#) – Durban, South Africa

SEATTLE – JUNE 6, 2018 – Funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health, and headquartered at the Fred Hutchinson Cancer Research Center, the [HVTN](#) will join study participants, communities and in-country partners to talk about its four [large-scale HIV vaccine efficacy clinical trials](#) that are fully enrolled or nearing full enrollment. These large-scale HIV vaccine efficacy clinical trials are underway in the conference host country, South Africa, and in 11 other countries across four continents.

As the world’s largest multi-disciplinary international collaboration facilitating the development of vaccines to prevent HIV, the HVTN is hosting and participating in the following activities, and invites stakeholders and the news media to attend:

Wednesday, June 12, Hall 1, 8:30-11:00 a.m.	Thursday, June 13, Hall 8 – 12AB, 7:30–8:30 a.m.
<p style="text-align: center;">Plenary:</p> <p>A journey to find a safe and effective HIV prevention response</p> <ul style="list-style-type: none"> ▪ Professor Linda-Gail Bekker, a principal investigator at the HVTN and Director of the Desmond Tutu HIV Centre at the University of Cape Town, will deliver a talk on the search for an HIV vaccine. ▪ Professor Glenda Gray, HVTN Co-Principal Investigator and President of the South Africa Medical Research Council, will be speaking on the role of broadly neutralizing antibodies (bnAbs) in the HIV prevention response. 	<p style="text-align: center;">Satellite session:</p> <p>The journey to find a safe & effective HIV vaccine</p> <p>This session, chaired by Professor Glenda Gray and Dr. Simba Takuva, will focus on the HVTN’s journey to find a safe and effective HIV vaccine and cover the topics of study participants and communities, HIV risk in women, partnerships, and updates on large-scale vaccine efficacy studies.</p> <p><i>Speakers will include:</i></p> <ul style="list-style-type: none"> ▪ Kagisho Baepanye, HVTN Community Engagement Manager ▪ Jackline Odhiambo, HVTN Senior Project Manager ▪ Dr. Fatima Laher, co-chair of HVTN 702, Principal Investigator and Director of PHRU Vaccines Research Clinical Research Site ▪ Dr. Mookho Malahleha, co-chair of HVTN 702 and Deputy Director of Setshaba Research Centre ▪ Dr. Kathryn Mngadi, co-chair for HVTN 705 and 107 and a CRS Leader for the Aurum Tembisa Clinic 4 ▪ Dr. Nyaradzo Mgodzi, co-chair of the Antibody Mediated Prevention (AMP) Studies

- News media interviews may be arranged before and after the activities. Please contact Aziel Gangerdine at azielg@fredhutch.org or at +1 206 384 0945.